4Q Revenues: $86.0 million (+18%)
4Q Earnings: $49.4 million (+27%)
FY Revenues: $374.5 million (+3%)
FY Earnings: $211.7 million (+6%)
Comments: Growth in the quarter was primarily driven by increased royalties from sales of Herceptin and Avastin, which are marketed by Genentech and Roche. Royalty revenues for the year were up 7%.